437 related articles for article (PubMed ID: 28050890)
1. Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy.
Mishra DK; Balekar N; Mishra PK
Drug Deliv Transl Res; 2017 Apr; 7(2):346-358. PubMed ID: 28050890
[TBL] [Abstract][Full Text] [Related]
2. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
[TBL] [Abstract][Full Text] [Related]
3. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers.
Ofek P; Fischer W; Calderón M; Haag R; Satchi-Fainaro R
FASEB J; 2010 Sep; 24(9):3122-34. PubMed ID: 20385622
[TBL] [Abstract][Full Text] [Related]
4. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects.
Seth S; Johns R; Templin MV
Ther Deliv; 2012 Feb; 3(2):245-61. PubMed ID: 22834200
[TBL] [Abstract][Full Text] [Related]
5. siRNA therapeutics: a clinical reality.
Saw PE; Song EW
Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
[TBL] [Abstract][Full Text] [Related]
6. Advances in siRNA delivery strategies for the treatment of MDR cancer.
Subhan MA; Attia SA; Torchilin VP
Life Sci; 2021 Jun; 274():119337. PubMed ID: 33713664
[TBL] [Abstract][Full Text] [Related]
7. Significance and applications of nanoparticles in siRNA delivery for cancer therapy.
Ali HM; Urbinati G; Raouane M; Massaad-Massade L
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):403-12. PubMed ID: 22943120
[TBL] [Abstract][Full Text] [Related]
8. Advances in siRNA delivery in cancer therapy.
Singh A; Trivedi P; Jain NK
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional nanocarrier based on clay nanotubes for efficient intracellular siRNA delivery and gene silencing.
Wu H; Shi Y; Huang C; Zhang Y; Wu J; Shen H; Jia N
J Biomater Appl; 2014 Apr; 28(8):1180-9. PubMed ID: 23985535
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
[TBL] [Abstract][Full Text] [Related]
11. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer.
Kala S; Mak AS; Liu X; Posocco P; Pricl S; Peng L; Wong AS
J Med Chem; 2014 Mar; 57(6):2634-42. PubMed ID: 24592939
[TBL] [Abstract][Full Text] [Related]
12. Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies.
Shajari N; Mansoori B; Davudian S; Mohammadi A; Baradaran B
Curr Drug Deliv; 2017; 14(1):36-46. PubMed ID: 27538460
[TBL] [Abstract][Full Text] [Related]
13. Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities.
Wang Z; Liu G; Zheng H; Chen X
Biotechnol Adv; 2014; 32(4):831-43. PubMed ID: 24013011
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of RNA interference against cancer.
Takeshita F; Ochiya T
Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
[TBL] [Abstract][Full Text] [Related]
15. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
Joo MK; Yhee JY; Kim SH; Kim K
J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
17. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
18. Delivery strategies for siRNA-mediated gene silencing.
Gilmore IR; Fox SP; Hollins AJ; Akhtar S
Curr Drug Deliv; 2006 Apr; 3(2):147-5. PubMed ID: 16611001
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of RNAi nanomedicines.
Barros SA; Gollob JA
Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]